RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy

Med. 2023 Dec 8;4(12):863-874. doi: 10.1016/j.medj.2023.09.001.


Emerging evidence suggests that local tumor radiotherapy reshapes the repertoire of circulating myeloid-derived suppressor cells (MDSCs) and leads to their infiltration into the tumor microenvironment, which poses a major obstacle for radiotherapy efficacy. Recent findings have identified RNA m6A modification at the nexus of both anti-tumor immunity and radiation response. Here, we examine the mechanisms by which this RNA modification modulates the immune milieu of the radiation-remodeled tumor microenvironment. We discuss potential therapeutic interventions targeting m6A machinery to improve radiotherapy response.

Publication types

  • Review

MeSH terms

  • Humans
  • Methylation
  • Myeloid-Derived Suppressor Cells* / pathology
  • Neoplasms* / genetics
  • Neoplasms* / radiotherapy
  • RNA
  • Tumor Microenvironment / genetics


  • RNA